Ethical and social recognition of participation in drug clinical trials: French public views on financial compensation for participants
PLOS One · 2026
DOI: 10.1371/journal.pone.0343321 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Laure Peyro-Saint-Paul und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, CHU Caen Normandy, Caen, France. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Public Opinion, Patient Participation, Compensation and Redress. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug clinical trial participants should be fairly compensated for inconvenience while avoiding undue inducement. However, European regulations provide limited operational guidance on when compensation should be offered and how it should be determined. The INDEM3 project aims to develop a decision-support tool for sponsors and ethics committees, beginning with an assessment of exploratory public perspectives in France.
Methods
An exploratory population-based survey was conducted using a self-administered questionnaire with an estimated completion time of approximately seven minutes. A minimum of 60 individuals was targeted, with or without chronic condition or prior research experience. The questionnaire assessed general views on financial compensation and responses to three fictional drug clinical trial scenarios varying in risk, burden, and direct benefit. Distribution occurred in healthcare settings and via social networks.
Results
Between March 2024 and January 2025, 65 responses were collected. Most respondents (75%) supported financial compensation for participation in drug clinical trials. The most frequently cited criteria were exposure to a new investigational drug (65%), invasive procedures (63%) and experiencing income lost (63%), and absence of direct personal benefit (28%). For the scenarios, the proportion of respondents supporting compensation and the median proposed amounts were as follows: Scenario 1 (no direct benefit, high burden, low uncertainty): 81%; €300 [€140–300]. Scenario 2 (some direct benefit, low burden, moderate uncertainty): 48%; €150 [€100–200]. Scenario 3 (some direct benefit, high burden and high uncertainty): 60%; €500 [€200–1,000].
Conclusion
Respondents in this exploratory French survey largely supported financial compensation for participation in drug clinical trials. Compensation is perceived as a proportionate ethical and social recognition of uncertainty, burden and lack of direct benefit. These findings provide an empirical basis for developing transparent tools to guide compensation decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clinical Research Department, CHU Caen Normandy, Caen, France.
- Caen Normandy University, Caen, France.
- NIMEC (Normandie Innovation Marché Entreprise Consommation), Caen, France.
- Comité de Protection des Personnes Nord Ouest III, Caen, France.
ORCID-Profile: Laure Peyro-Saint-Paul, Michael Joubert
Zitieren
APA
Peyro-Saint-Paul, L., Gaillard, C., Berchi, C., Gakuba, C., Gourio, C., Grandazzi, G., Joubert, M., Brucato, S., Bechade, C., Morello, R., & INDEM Working Group (2026). Ethical and social recognition of participation in drug clinical trials: French public views on financial compensation for participants. PLOS One. https://doi.org/10.1371/journal.pone.0343321
Vancouver
Peyro-Saint-Paul L, Gaillard C, Berchi C, Gakuba C, Gourio C, Grandazzi G, et al. Ethical and social recognition of participation in drug clinical trials: French public views on financial compensation for participants. PLOS One. 2026. doi:10.1371/journal.pone.0343321
BibTeX
@article{PeyroSaintPaul2026,
author = {Peyro-Saint-Paul, Laure and Gaillard, Cathy and Berchi, Célia and Gakuba, Clément and Gourio, Charlotte and Grandazzi, Guillaume and Joubert, Michael and Brucato, Sylvie and Bechade, Clémence and Morello, Rémy and INDEM Working Group, INDEM Working Group},
title = {Ethical and social recognition of participation in drug clinical trials: French public views on financial compensation for participants},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0343321}
}
EUVIMED